TSC1 and cancer: Despite significant clinical successes, that have led to the use of mTOR inhibitors, both as monotherapy and in synergistic combinations with other agents, in the treatment of several human cancers and genetic conditions, such as the TSC complex, many aspects of the mTOR pathway still remain to be explored.